1-[(2R,3R,4R,5R)-5-[2-[dimethyl(methylidene)-lambda5-phosphanyl]ethyl]-4-hydroxy-3-methoxyoxolan-2-yl]-5-[(2-oxopropylamino)methyl]-2-sulfanylidenepyrimidin-4-one

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 5'-脱氧核糖核苷
• 英文名称: 1-[(2R,3R,4R,5R)-5-[2-[dimethyl(methylidene)-lambda5-phosphanyl]ethyl]-4-hydroxy-3-methoxyoxolan-2-yl]-5-[(2-oxopropylamino)methyl]-2-sulfanylidenepyrimidin-4-one
• 英文别名: 1-[(2R,3R,4R,5R)-5-[2-[dimethyl(methylidene)-λ5-phosphanyl]ethyl]-4-hydroxy-3-methoxyoxolan-2-yl]-5-[(2-oxopropylamino)methyl]-2-sulfanylidenepyrimidin-4-one
• 化学式: C₁₈H₃₀N₃O₅PS
• 分子量: 431.5
• InChiKey: BBVYBCQQRKSVMN-KCYZZUKISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  132
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• MODIFIED POLYNUCLEOTIDES FOR TREATING ARYLSULFATASE A PROTEIN DEFICIENCY
  申请人：MODERNA THERAPEUTICS, INC.

  公开号：US20140206755A1

  公开（公告）日：2014-07-24

  The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
• HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA
  申请人：MODERNA THERAPEUTICS, INC.

  公开号：US20160022840A1

  公开（公告）日：2016-01-28

  The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
• ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF
  申请人：Moderna Therapeutics, Inc.

  公开号：US20170136131A1

  公开（公告）日：2017-05-18

  The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them.